Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.jsat.2020.108263 http://scihub22266oqcxt.onion/10.1016/j.jsat.2020.108263 33612196!7900610!33612196     free     free     free Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Subst+Abuse+Treat 2021 ; 123 (ä): 108263 Nephropedia Template TP {{tp|p=33612196|t=2021. Leveraging COVID-19 to sustain regulatory flexibility in the treatment of opioid use disorder |pdf=|usr=}}{{33612196}} gab.com Text Leveraging COVID-19 to sustain regulatory flexibility in the treatment of opioid use disorder JO: J Subst Abuse Treat http://www.kidney.de/pget.php?&tw=1&pmid=33612196 #FOAvip The U.S. government declared the opioid epidemic as a national public health emergency in 2017, but regulatory frameworks that govern the treatment of opioid use disorder (OUD) through pharmaceutical interventions have remained inflexible. The emergence of the COVID-19 pandemic has effectively removed regulatory restrictions that experts in the field of medications for opioid use disorder (MOUD) have been proposing for decades and has expanded access to care. The regulatory flexibilities implemented to avoid unnecessary COVID-related death must be made permanent to ensure that improved access to evidence-based treatment remains available to vulnerable individuals with OUD who otherwise face formidable barriers to MOUD. We must seize this moment of COVOD-19 regulatory flexibilities to demonstrate the feasibility, acceptability, and safety of delivering treatment for OUD through a low-threshold approach. Twit Text FOAVip Leveraging COVID-19 to sustain regulatory flexibility in the treatment of opioid use disorder ????J Subst Abuse Treat http://www.kidney.de/pget.php?&tw=1&pmid=33612196 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33612196 #FOAvip English Wikipedia <ref>{{Cite pmid|33612196}}</ref> Leveraging COVID-19 to sustain regulatory flexibility in the treatment of opioid use disorder #MMPMID33612196 Stringer KL; Langdon KJ; McKenzie M; Brockmann B; Marotta P J Subst Abuse Treat 2021[Apr]; 123 (ä): 108263 PMID33612196show ga The U.S. government declared the opioid epidemic as a national public health emergency in 2017, but regulatory frameworks that govern the treatment of opioid use disorder (OUD) through pharmaceutical interventions have remained inflexible. The emergence of the COVID-19 pandemic has effectively removed regulatory restrictions that experts in the field of medications for opioid use disorder (MOUD) have been proposing for decades and has expanded access to care. The regulatory flexibilities implemented to avoid unnecessary COVID-related death must be made permanent to ensure that improved access to evidence-based treatment remains available to vulnerable individuals with OUD who otherwise face formidable barriers to MOUD. We must seize this moment of COVOD-19 regulatory flexibilities to demonstrate the feasibility, acceptability, and safety of delivering treatment for OUD through a low-threshold approach. |*COVID-19[MESH] |*Health Services Needs and Demand[MESH] |*SARS-CoV-2[MESH] |Buprenorphine/administration & dosage/therapeutic use[MESH] |Humans[MESH] |Methadone[MESH] |Narcotic Antagonists/administration & dosage/therapeutic use[MESH] |Opiate Substitution Treatment/*trends[MESH] |Opioid-Related Disorders/*rehabilitation[MESH]Leveraging COVID-19 to sustain regulatory flexibility in the treatment(epmc).pdf DeepDyve Pubget Overpricing